Overexpressed on the surface of prostate cancer cells, PSMA provides a tumor-specific binding site for radioligands suited for both positron emission tomography (PET) imaging and radioligand therapy (RLT) [1]. The gene discussed is FOLH1; the disease is prostate cancer.